HilleVax (NASDAQ:HLVX) Cut to Neutral at Guggenheim

Guggenheim downgraded shares of HilleVax (NASDAQ:HLVXFree Report) from a buy rating to a neutral rating in a research note published on Monday morning, Marketbeat reports.

Several other research firms have also issued reports on HLVX. HC Wainwright reiterated a buy rating and issued a $28.00 target price on shares of HilleVax in a research note on Friday, May 10th. JPMorgan Chase & Co. restated a neutral rating and set a $5.00 price target (down previously from $24.00) on shares of HilleVax in a research report on Monday. Six equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, HilleVax currently has a consensus rating of Hold and a consensus price target of $9.20.

Check Out Our Latest Report on HilleVax

HilleVax Stock Performance

HLVX opened at $1.63 on Monday. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.11. The company’s fifty day moving average price is $13.04 and its two-hundred day moving average price is $14.59. HilleVax has a 1-year low of $1.55 and a 1-year high of $20.22. The company has a market cap of $81.04 million, a price-to-earnings ratio of -0.49 and a beta of 0.78.

HilleVax (NASDAQ:HLVXGet Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.13). On average, analysts expect that HilleVax will post -3.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other HilleVax news, Director Aditya Kohli sold 6,000 shares of the stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $14.73, for a total transaction of $88,380.00. Following the completion of the transaction, the director now owns 764,878 shares in the company, valued at $11,266,652.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 12,898 shares of company stock worth $193,766 over the last quarter. 71.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On HilleVax

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HLVX. Federated Hermes Inc. boosted its position in HilleVax by 80.6% during the third quarter. Federated Hermes Inc. now owns 2,113 shares of the company’s stock worth $28,000 after purchasing an additional 943 shares during the period. EntryPoint Capital LLC bought a new position in HilleVax during the first quarter worth about $80,000. SG Americas Securities LLC bought a new position in HilleVax during the fourth quarter worth about $139,000. Tidal Investments LLC bought a new position in HilleVax during the first quarter worth about $207,000. Finally, abrdn plc purchased a new stake in shares of HilleVax in the fourth quarter worth about $433,000. Institutional investors own 86.42% of the company’s stock.

HilleVax Company Profile

(Get Free Report)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

Featured Articles

Analyst Recommendations for HilleVax (NASDAQ:HLVX)

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.